First-Line Therapies

Medical Advocates
ARV/HAART/cART

First Line ARV Regimens

General Reports
Protease-Inhibitor-Based Therapies
NRTI-Based Therapies
NNRTI-Based Therapies
Drug-Specific Therapies

Starting ARV Therapy Main New/Newsworthy Home Page

Last Update: February 27, 2015
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports

Journal Papers, Abstracts, and Commentaries

Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort.
Di Biagio A, Cozzi-Lepri A, Prinapori R, et al
J Int AIDS Soc. 2014 Nov 2;17(4(Suppl 3)):19825.
Abstract

FULL-TEXT ARTICLE
A Very Low Geno2pheno False Positive Rate Is Associated with Poor Viro-Immunological Response in Drug-Naīve Patients Starting a First-Line HAART.
Armenia D, Soulie C, Di Carlo D, et al
PLoS One. 2014 Aug 25;9(8):e105853.
Paper

Evaluating immunologic response and clinical deterioration in treatment-naīve patients initiating first-line therapies infected with HIV-1 CRF01_AE and subtype B.
Oyomopito RA, Li PC, et al on behalf of the TREAT Asia Studies to Evaluate Resistance (TASER) and the TREAT Asia HIV Observational Database.
J Acquir Immune Defic Syndr. 2012 Nov 7.
Abstract

FULL-TEXT ARTICLE
What is the optimal first line antiretroviral therapy in resource-limited settings?
Kenyon C, Colebunders R.
PLoS Med. 2012 Aug;9(8):e1001291.
Papers

Initial Viral Decay to Assess the Relative Antiretroviral Potency of PI-, NNRTI- and NRTI-Sparing Regimens for
First Line Therapy of HIV Infection.
Haubrich RH, Riddler SA, Ribaudo H, et al
AIDS. 2011 Sep 21.
Abstract

Clinical management of acute HIV infection: best practice remains unknown.
Bell SK, Little SJ, Rosenberg ES.
J Infect Dis. 2010 Oct 15;202 Suppl 2:S278-88.
Abstract

Determinants of virological failure after successful viral load suppression in first-line highly active
antiretroviral therapy.
Geretti AM, Smith C, Haberl A, , et al
Antivir Ther. 2008;13(7):927-36.
Abstract

Class-sparing regimens for initial treatment of HIV-1 infection.
Riddler SA, Haubrich R, DiRienzo AG, et al
N Engl J Med. 2008 May 15;358(20):2095-106.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Patterns, predictors, and consequences of initial regimen type among HIV-infected
women receiving highly active antiretroviral therapy.
Golub ET, Benning L, Sharma A, et al
Clin Infect Dis. 2008 Jan 15;46(2):305-12
Abstract

A comparison of three highly active antiretroviral treatment strategies consisting of
non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the
presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058
FIRST Study): a long-term randomised trial.
MacArthur RD, Novak RM, Peng G, et al
Lancet. 2006 Dec 16;368(9553):2107-9.
Abstract

A randomized study comparing a three- and four-drug HAART regimen in first-line therapy
(QUAD study).
Orkin C, Stebbing J, Nelson M, et al
J Antimicrob C J Antimicrob Chemother. 2004 Dec 17
Abstract

Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study.
Galli M, Cozzi-Lepri A, Ridolfo AL
Arch Intern Med 2002 Dec 9-23;162(22):2621-8
Abstract

Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in
previously drug-naive individuals.
Phillips AN, Miller V, Sabin C, et al.
AIDS 2001 Dec 7;15(18):2379-84
Abstract

Conference Reports, Abstracts, and Posters

POSTER
The choice of first-line regimen influences the likelihood of therapy switches and disease progression
V.D. Lima, Y. Chen, T. Kozai, et al
(7th IAS Conference)
Poster Abstract

Comparison of the efficacy at 48 weeks of first-line antiretroviral treatment for HIV infection in 1998 and 2006:
a multicentric investigation
F Sozio, V Soddu, G De Socio,et al
(Ninth International Congress on Drug Therapy in HIV Infection)
Abstract

Protease-Inhibitor-Based Therapies

Journal Papers, Abstracts, and Commentaries

Secondary mutations in the protease region of human immunodeficiency virus
and virologic failure n drug-naive patients treated with protease inhibitor-based therapy.
Perno CF, Cozzi-Lepri A, Balotta C, et al.
J Infect Dis 2001 Oct 15;184(8):983-91
Abstract

NRTI-Based Therapies: General

Journal Papers, Abstracts, and Commentaries

FULL-TEXT PDF ARTICLE
The Choice of the Nucleoside Backbone in Initial Therapy
Gallant JE
The Hopkins HIV Report, November 2004 Vol 16. No 6
Paper

First-line therapy and mitochondrial damage: different nucleosides, different findings.
Blanco F, Garcia-Benayas T, Jose De La Cruz J
HIV Clin Trials 2003 Jan-Feb;4(1):11-99
Abstract

Simplification of antiretroviral treatment--how to sustain success, reduce toxicity and
ensure adherence avoiding PI use.
Barreiro P, Garcia-Benayas T, Soriano V, Gallant J.
AIDS Rev 2002 Oct-Dec;4(4):233-41
Abstract

A rational approach to the selection and sequencing of nucleoside/nucleotide analogues:
a new paradigm.
Lange J.
Antivir Ther 2001;6 Suppl 3:45-54
Abstract

NNRTI-Based Therapies: General

Journal Papers, Abstracts, and Commentaries

First-line therapy and mitochondrial damage: different nucleosides, different findings.
Blanco F, Garcia-Benayas T, Jose De La Cruz J
HIV Clin Trials 2003 Jan-Feb;4(1):11-99
Abstract

Simplification of antiretroviral treatment--how to sustain success, reduce toxicity and
ensure adherence avoiding PI use.
Barreiro P, Garcia-Benayas T, Soriano V, Gallant J.
AIDS Rev 2002 Oct-Dec;4(4):233-41
Abstract

Starting ARV Therapy Main New/Newsworthy Home Page

First Line ARV Regimens